FocalTherics (Nasdaq: FOCL) reported third-quarter 2026 revenue of $9.8 million, alongside higher U.S. procedure volume and a narrower net loss. Revenue rose 26% year over year, U.S. procedures increased 32%, and seven Focal One systems were sold versus six. Gross margin improved to 51.4% from 46.6%.
Operating loss widened to $7.8 million from $6.7 million. Net loss narrowed to $4.5 million, or $0.10 per share, from $5.9 million, or $0.16 per share, helped by a $2.6 million non-cash warrant valuation gain. Nine-month revenue increased 45%, while U.S. procedure volume grew 44%.
The company narrowed its 2026 revenue outlook to $50.0–$52.0 million from $50.0–$54.0 million, representing expected growth of 34%–39% over 2025. Cash, cash equivalents and short-term investments totaled $56.269 million at September 30. Commercial endometriosis programs expanded to three European centers.
FocalTherics (Nasdaq: FOCL) will participate in upcoming investor conferences, starting with the UBS Global Healthcare Conference on November 10, 2026.
Management is scheduled for a UBS fireside chat at 1:15 pm ET, one-on-one meetings at the Jefferies Global Healthcare Conference in London on November 18, and a Piper Sandler 38th Annual Healthcare Conference fireside chat on December 2 at 4:00 pm ET.
FocalTherics (FOCL) will release its third-quarter 2026 financial results after market close on November 5, 2026. The results cover the quarter ended September 30, 2026. Chief Executive Officer Ryan Rhodes and Chief Financial Officer Ken Mobeck will conduct a conference call and webcast at 4:30 p.m. Eastern Time that day.
FocalTherics (Nasdaq: FOCL) announced that CEO Ryan Rhodes will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, held September 14-16, 2026. The company’s presentation is scheduled for Tuesday, September 15, 2026, from 10:30-11:00 AM ET and will be webcast live.
Rhodes and CFO Ken Mobeck will also host 1x1 investor meetings on September 15-16, 2026. A live and archived webcast of the presentation will be available via the provided conference link and through the Investors section of FocalTherics’ website.
FocalTherics (Nasdaq: FOCL) reported second quarter 2026 continuing-operations (HIFU segment) revenue of $13.2 million, up 39% year-over-year, with U.S. Focal One procedure volume increasing 47%. The company sold 13 Focal One systems versus 9 a year ago and expanded its installed base to 184 systems worldwide.
Gross margin improved to 55.6% from 51.1%, while operating expenses rose to $15.4 million, including about $0.8 million of one-time rebranding and transition costs. FocalTherics posted an operating loss of $8.0 million and a net loss of $14.5 million (loss per share $0.39), influenced by a $5.5 million warrant valuation impact. Cash and equivalents were $21.5 million at June 30, 2026. The company reiterated 2026 HIFU revenue guidance of $50–54 million, implying 34–45% growth, completed its corporate name change, launched its first commercial Focal One endometriosis program in Europe, and announced a $40 million underwritten public offering expected to close August 14, 2026. ESWL and Distribution businesses are now classified as discontinued operations.
FocalTherics (NASDAQ: FOCL) has priced an underwritten public offering of 8,425,000 American Depositary Shares (ADSs), each representing one ordinary share with €0.13 nominal value, at a public offering price of $4.75 per ADS, before underwriting discounts and commissions.
All ADSs will be sold by the company, which expects gross proceeds of about $40.0 million, excluding the underwriters’ 30‑day option to buy up to 1,263,750 additional ADSs. The offering, made under an effective Form S‑3 shelf registration, is expected to close on August 14, 2026, subject to customary conditions. TD Cowen and Mizuho are joint book‑running managers, with H.C. Wainwright & Co. and Lucid Capital Markets as co‑managers.
FocalTherics (Nasdaq: FOCL) reported preliminary, unaudited second-quarter 2026 results for its HIFU segment, now presented as continuing operations. The ESWL and Distribution segments met criteria to be classified as held for sale and are reported as discontinued operations, reflecting a strategic shift expected to significantly affect operations and financial results.
For Q2 2026, HIFU segment revenue is estimated between $12.7–$13.2 million, up 34%–39% year over year, with gross margin between 54%–56%, an increase of 3%–5%. Cash, cash equivalents and short-term investments from all operations totaled $21.5 million as of June 30, 2026. These figures are preliminary, unaudited and subject to change. FocalTherics plans to release full Q2 2026 results and host a conference call on August 13, 2026.
FocalTherics (NASDAQ: FOCL) has commenced an underwritten public offering of American Depositary Shares (ADSs), each representing one ordinary share with a nominal value of €0.13. All ADSs will be sold by the company, which also plans to grant underwriters a 30‑day option to purchase up to an additional 15% of the ADSs on the same terms.
The final terms, size and pricing of the offering will be determined later and completion is subject to market conditions. According to the company, net proceeds are intended for operating costs, capital expenditures and general corporate purposes, including working capital. The offering is being made under an effective shelf registration statement on Form S‑3, with TD Cowen and Mizuho as joint book‑running managers and H.C. Wainwright & Co. and Lucid Capital Markets as co‑managers.
FocalTherics (Nasdaq: FOCL) will release its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time, led by CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch.
FocalTherics (Nasdaq: FOCL) launched the first European commercial endometriosis Focal One program at Toulouse University Hospital, where initial patients have been treated. The hospital acquired Focal One to treat deep infiltrating endometriosis and prostate cancer. More than 10 hospitals are in active clinical training across Europe, the UK, and Latin America.
Focal One Robotic HIFU uses imaging and high-intensity focused ultrasound to ablate bowel and rectal endometriosis lesions without incisions, aiming to preserve surrounding tissue. It received CE Mark in March 2025 for posterior deep infiltrating endometriosis and is commercially available in CE Mark countries and select markets.